Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs

25 Feb 2021

CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.

Back view image of young businessman standing against business sketch — Analysts wonder if Intercept is de-emphasizing NASH to focus on PBC

Market analysts have been trying to read the tea leaves regarding Intercept Pharmaceuticals, Inc.’s prospects for getting obeticholic acid (OCA) refiled for US approval in non-alcoholic steatohepatitis for months now, and while the firm’s fourth quarter/full-year 2020 earnings call on 25 February offered assurances about refiling the new drug application by year’s end, those same analysts don’t seem fully convinced.

New CEO Jerome Durso, promoted from chief operating officer on 1 January as long-time former CEO Mark Pruzanski retired and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

04 Jul 2025

• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Novartis’s Cosentyx Suffers Rare Phase III Fail

03 Jul 2025

• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

02 Jul 2025

• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.